MA53074A - Dérivés d'oxadiazolopyridine à substitution hétérocyclyle utilisés en tant qu'inhibiteurs de la ghréline o-acyltransférase (goat) - Google Patents

Dérivés d'oxadiazolopyridine à substitution hétérocyclyle utilisés en tant qu'inhibiteurs de la ghréline o-acyltransférase (goat)

Info

Publication number
MA53074A
MA53074A MA053074A MA53074A MA53074A MA 53074 A MA53074 A MA 53074A MA 053074 A MA053074 A MA 053074A MA 53074 A MA53074 A MA 53074A MA 53074 A MA53074 A MA 53074A
Authority
MA
Morocco
Prior art keywords
ghrelin
acyltransferase
goat
inhibitors
derivatives used
Prior art date
Application number
MA053074A
Other languages
English (en)
Inventor
Cédrickx Godbout
Thomas Trieselmann
Viktor Vintonyak
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA53074A publication Critical patent/MA53074A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA053074A 2018-02-02 2019-01-28 Dérivés d'oxadiazolopyridine à substitution hétérocyclyle utilisés en tant qu'inhibiteurs de la ghréline o-acyltransférase (goat) MA53074A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18154828 2018-02-02

Publications (1)

Publication Number Publication Date
MA53074A true MA53074A (fr) 2021-05-12

Family

ID=61157053

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053074A MA53074A (fr) 2018-02-02 2019-01-28 Dérivés d'oxadiazolopyridine à substitution hétérocyclyle utilisés en tant qu'inhibiteurs de la ghréline o-acyltransférase (goat)

Country Status (21)

Country Link
US (1) US11319310B2 (fr)
EP (1) EP3746450B1 (fr)
JP (1) JP7150032B2 (fr)
KR (1) KR20200118124A (fr)
CN (1) CN111655699B (fr)
AU (1) AU2019215709A1 (fr)
BR (1) BR112020014320A2 (fr)
CA (1) CA3087827A1 (fr)
CL (1) CL2020001908A1 (fr)
CO (1) CO2020009179A2 (fr)
CR (1) CR20200331A (fr)
EA (1) EA202091804A1 (fr)
EC (1) ECSP20050791A (fr)
IL (1) IL276137A (fr)
JO (1) JOP20200191A1 (fr)
MA (1) MA53074A (fr)
MX (1) MX2020008116A (fr)
PE (1) PE20210175A1 (fr)
PH (1) PH12020551169A1 (fr)
SG (1) SG11202006300XA (fr)
WO (1) WO2019149659A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS61937B1 (sr) * 2016-08-05 2021-07-30 Boehringer Ingelheim Int Oksadiazolopiridin derivati za primenu kao inhibitori grelin o-acil transferaze (goat)
JOP20200187A1 (ar) 2018-02-02 2020-07-29 Boehringer Ingelheim Int مشتقات ترايازولو بيريميدين للاستخدام كمثبطات جريلين o- أسيل ترانسفيراز (goat)
CN111655700B (zh) 2018-02-02 2023-07-18 勃林格殷格翰国际有限公司 作为饥饿素o-酰基转移酶(goat)抑制剂的噁二唑并吡啶衍生物
CN111630055B (zh) * 2018-02-02 2023-07-14 勃林格殷格翰国际有限公司 用作饥饿素o-酰基转移酶(goat)抑制剂的吡唑取代的和吲唑取代的噁二唑并吡啶衍生物
CA3173731A1 (fr) 2020-02-28 2021-09-02 Kallyope, Inc. Agonistes de gpr40
PL4153600T3 (pl) 2020-05-22 2024-12-16 Boehringer Ingelheim International Gmbh Sposób ciągły wytwarzania 7-amino-5-metylo-[1,2,5]oksadiazolo[3,4- b]pirydynokarboksylanu alkilu
EP4153599B1 (fr) * 2020-05-22 2024-03-13 Boehringer Ingelheim International GmbH Procédé de fabrication de 7-amino-5-méthyl- [1,2,5] oxadiazolo [3,4-b] pyridine-carboxylate d'alkyle

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004082383A1 (fr) 2003-03-17 2004-09-30 Basf Aktiengesellschaft Utilisation de triazolopyrimidines pour combattre les nematodoses de vegetaux
MX2009008241A (es) 2007-02-15 2009-10-08 Univ Indiana Res & Tech Corp Co-agonistas de receptor de glucagon/glp-1.
JP5385266B2 (ja) 2007-06-15 2014-01-08 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
MX2011006314A (es) 2008-12-15 2011-09-22 Zealand Pharma As Analogos de glucagon.
EA020537B1 (ru) 2008-12-15 2014-11-28 Зилэнд Фарма А/С Аналоги глюкагона
PL2370462T3 (pl) 2008-12-15 2015-01-30 Zealand Pharma As Analogi glukagonu
AU2008365557A1 (en) 2008-12-15 2011-07-21 Zealand Pharma A/S Glucagon analogues
AP3329A (en) 2009-07-13 2015-06-30 Zealand Pharma As Acylated glucagon analogues
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
KR20130086343A (ko) 2010-06-24 2013-08-01 질랜드 파마 에이/에스 글루카곤 유사체
KR20140114845A (ko) 2011-12-23 2014-09-29 질랜드 파마 에이/에스 글루카곤 유사체
US9238639B2 (en) 2012-02-24 2016-01-19 Takeda Pharmaceutical Company Limited Aromatic ring compound
WO2013192388A1 (fr) 2012-06-20 2013-12-27 University Of Virginia Patent Foundation Compositions et procédés pour réguler l'homéostasie du glucose et l'action de l'insuline
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
UA118034C2 (uk) 2013-11-14 2018-11-12 Елі Ліллі Енд Компані Заміщений піперидилетилпіримідин як інгібітор грелін-o-ацилтрансферази
EP3193939A4 (fr) 2014-09-17 2018-10-24 The Regents of The University of California Petits inhibiteurs lipopeptidomimétiques de la ghréline o-acyl transférase
WO2016123275A1 (fr) 2015-01-30 2016-08-04 Boehringer Ingelheim International Gmbh Inhibiteurs de l'aldostérone synthase
AR104672A1 (es) 2015-04-15 2017-08-09 Lilly Co Eli Inhibidores de grelina o-aciltransferasa
AR104673A1 (es) 2015-04-15 2017-08-09 Lilly Co Eli Inhibidores de grelina o-aciltransferasa
RS61937B1 (sr) * 2016-08-05 2021-07-30 Boehringer Ingelheim Int Oksadiazolopiridin derivati za primenu kao inhibitori grelin o-acil transferaze (goat)

Also Published As

Publication number Publication date
CO2020009179A2 (es) 2020-07-31
KR20200118124A (ko) 2020-10-14
CL2020001908A1 (es) 2020-10-30
US11319310B2 (en) 2022-05-03
CN111655699B (zh) 2023-07-14
CN111655699A (zh) 2020-09-11
MX2020008116A (es) 2020-09-25
WO2019149659A1 (fr) 2019-08-08
ECSP20050791A (es) 2020-09-30
PH12020551169A1 (en) 2021-05-31
EP3746450B1 (fr) 2022-03-16
EP3746450A1 (fr) 2020-12-09
AU2019215709A1 (en) 2020-07-16
JOP20200191A1 (ar) 2020-07-29
PE20210175A1 (es) 2021-01-29
SG11202006300XA (en) 2020-07-29
BR112020014320A2 (pt) 2020-12-08
EA202091804A1 (ru) 2020-12-24
CA3087827A1 (fr) 2019-08-08
IL276137A (en) 2020-09-30
JP7150032B2 (ja) 2022-10-07
JP2021512112A (ja) 2021-05-13
US20210040077A1 (en) 2021-02-11
CR20200331A (es) 2020-09-03

Similar Documents

Publication Publication Date Title
MA52486A (fr) Pyridazinones utilisés en tant qu'inhibiteurs de parp7
MA54076A (fr) 2-amino-n-hétéroaryl-nicotinamides utilisés en tant qu'inhibiteurs de nav1.8
EP3873468A4 (fr) 2-amino-n-phényl-nicotinamides utilisés en tant qu'inhibiteurs de nav1.8
MA51774A (fr) Dérivés de triazolopyrimidine destinés à être utilisés en tant qu'inhibiteurs de la ghréline o-acyltransférase (goat)
EP3768671A4 (fr) Dérivés d'imidazolidine-2-one substitués en tant qu'inhibiteurs de prmt5
MA53075A (fr) Dérivés d'oxadiazolopyridine à substitution benzyle, (pyridin-3-yl)méthyle ou (pyridin-4-yl)méthyle utilisés en tant qu'inhibiteurs de la ghréline o-acyltransférase (goat)
EP3768661A4 (fr) Composés deutérés utilisés en tant qu'inhibiteurs de rock
MA52189A (fr) Benzothiophènes et composés associés utilisés en tant qu'agonistes de sting
MA54452A (fr) Dérivés de 2-oxoquinazoline utilisés en tant qu'inhibiteurs de la méthionine adénosyltransférase 2a
MA53220A (fr) Nouveaux composés hétérocycliques utilisés en tant qu'inhibiteurs de monoacylglycérol lipase
MA51431A (fr) Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase
EP3733671A4 (fr) Dérivés amino-fluoropipéridines utilisés en tant qu'inhibiteur de kinase
MA49888A (fr) Composés macrocycliques utilisés en tant qu'inhibiteurs de kinase ros1
MA43169A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma
MA53229A (fr) Amides de diméthyl amino azétidine utilisés en tant qu'inhibiteurs de jak
MA51438A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1
MA42659A (fr) Dérivés hétéroaryle utilisés en tant qu'inhibiteurs de parp
EP3781574A4 (fr) Spiroéthers macrocycliques utilisés en tant qu'inhibiteurs de mcl-1
MA49374A (fr) Composés hétéroaromatiques utilisés en tant qu'inhibiteurs de vanine
EP3752144A4 (fr) Composés hétérocycliques tricycliques utiles en tant qu'inhibiteurs de l'intégrase du vih
MA47086A (fr) Dérivés de dihydropyrimidine-carboxamide bicycliques utilisés en tant qu'inhibiteurs de rho-kinase
MA52367A (fr) Composés hétérocycliques tricycliques utiles en tant qu'inhibiteurs de l'intégrase du vih
MA50439A (fr) Nouveaux dérivés de pyrazolo-pyrrolo-pyrimidine-dione utilisés en tant qu'inhibiteurs de p2x3
MA56208A (fr) Composés pyrazole disubstitués utilisés en tant qu'inhibiteurs de cétohexokinase
MA50013A (fr) Analogues de benzoazépine utilisés en tant qu'agents inhibiteurs de la tyrosine kinase de bruton